Oncology, a complex specialty, stands to gain significantly from advancements in healthcare technology. With health care turning increasingly digital over the past 2 decades, many new and exciting ...

NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its ...

Malcolm Ethridge, Capital Area Planning Group managing partner, joined CNBC to talk about where the market could go and his ...

According to The Insight Partners study on the Radiation Oncology Market is observing significant growth owing to the ...

The global clinical next-generation sequencing (NGS) data analysis market opportunity enjoys a valuation of USD 2.3 Billion in 2023, and it is further projected to expand at a CAGR of 17.4% over the ...

The global high potency API (HPAPI) contract manufacturing market achieved a market value of USD 8 billion in 2022 and is ...

Diakonos’ dendritic cell vaccine represents a unique approach for engaging an immune response against a patient’s cancer.

As global markets experience shifts with interest rate adjustments and economic indicators showing mixed signals, the Hong Kong market remains a focal point for investors seeking opportunities in high ...

On September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant addition to its investment ...

The Swiss market recently demonstrated resilience by rebounding from a weak start, buoyed by the European Central Bank's interest rate cut to 3.25%, which helped lift the SMI index by 0.91% to close ...

AKT1 E17K mutation is a clinically validated oncogene that impacts greater than 40,000 cancer patients per year in the United States, with the highest prevalence in breast, endometrial, and prostate ...